Ramelteon (Rozerem) for insomnia

Medical Letter on Drugs and Therapeutics

Volumn 47, Issue 1221, 2005, Pages 89-91

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CIPROFLOXACIN; DIPHENHYDRAMINE; ESZOPICLONE; FLUVOXAMINE; FLUVOXAMINE MALEATE; MELATONIN; MELATONIN RECEPTOR AGONIST; OMEPRAZOLE; PROLACTIN; RAMELTEON; RIFAMPICIN; STARNOC; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE; INDENE DERIVATIVE; MELATONIN 1 RECEPTOR;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; FATIGUE; HALF LIFE TIME; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; INFERTILITY; INSOMNIA; LIBIDO DISORDER; LIVER CARCINOGENESIS; NAUSEA; NONHUMAN; OSTEOPOROSIS; REBOUND; SHORT SURVEY; SOMNOLENCE; TERATOGENICITY; ARTICLE;

HUMANS; INDENES; MELATONIN; RECEPTOR, MELATONIN, MT1; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33644635057     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. FW Turek and MU Gillette. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5:523.
2. J Montplaisir et al. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Hum Psychopharmacol 2003; 18:29.
3. Zolpidem for insomnia. Med Lett Drugs Ther 1993; 35:35.
4. Eszopiclone (Lunesta), a new hypnotic. Med Lett Drugs Ther 2005; 47:17.
5. K Kato et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48:301.
6. C Cajochen et al. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6:114.
7. M Miyamoto et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004; 27:1319.
8. M Erman et al. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia. Sleep 2003; 26 abstract suppl:A298.
9. G Zammit et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep 2005; 28 abstract suppl:A228.
10. Summary from Takeda Pharmaceuticals.
11. T Roth et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc 2005; 53 (suppl):S25.
12. T Roth et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia [abstract 87]. New Clinical Drug Evaluation Unit, 45th annual meeting, June 6-9 2005, Boca Raton, Fla. Poster Session II, p. 303. Available at www.nimh.nih.gov/ncdeu/index.cfm. Accessed October 26, 2005.
13. T Roth et al. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005; 28:303.
14. Summary from Takeda Pharmaceuticals.
15. R Griffiths et al. Ramelteon and triazolam in humans: behavioral effects and abuse potential. Sleep 2005; 28 abstract suppl:A44.
16. Drug interactions. Med Lett Drugs Ther 2003; 45:46.